Gregory Kearns
Gregory Kearns
President, Arkansas Children's Research Institute
Verified email at
Cited by
Cited by
Developmental pharmacology—drug disposition, action, and therapy in infants and children
GL Kearns, SM Abdel-Rahman, SW Alander, DL Blowey, JS Leeder, ...
New England Journal of Medicine 349 (12), 1157-1167, 2003
Handbook of basic pharmacokinetics
WA Ritschel
Drug Intelligence Publications, 1976
Cytochrome P450 3A
SN de Wildt, GL Kearns, JS Leeder, JN van den Anker
Clinical pharmacokinetics 37 (6), 485-505, 1999
Glucuronidation in humans
SN de Wildt, GL Kearns, JS Leeder, JN van den Anker
Clinical pharmacokinetics 36 (6), 439-452, 1999
Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children
C Pihoker, GL Kearns, D French, CY Bowers
The Journal of Clinical Endocrinology & Metabolism 83 (4), 1168-1172, 1998
Pharmacogenetics in pediatrics: implications for practice
JS Leeder, GL Kearns
Pediatric Clinics of North America 44 (1), 55-77, 1997
Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data.
A Gaedigk, RR Gotschall, NS Forbes, SD Simon, GL Kearns, JS Leeder
Pharmacogenetics 9 (6), 669-682, 1999
Clinical pharmacokinetics in infants and children
GL Kearns, MD Reed
Clinical pharmacokinetics 17 (1), 29-67, 1989
Acute hepatic failure associated with the use of sodium valproate: report of two fatal cases
FJ Suchy, WF Balistreri, JJ Buchino, JM Sondheimer, SR Bates, ...
New England Journal of Medicine 300 (17), 962-966, 1979
The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants
GP Heresi, DR Gerstmann, MD Reed, JN van den Anker, JL Blumer, ...
The Pediatric infectious disease journal 25 (12), 1110-1115, 2006
Ontogeny of drug metabolizing enzymes in the neonate
MJ Blake, L Castro, JS Leeder, GL Kearns
Seminars in Fetal and Neonatal Medicine 10 (2), 123-138, 2005
Proton pump inhibitors in pediatrics
RM Ward, GL Kearns
Pediatric Drugs 15 (2), 119-131, 2013
Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N‐acetyltransferase‐2, and xanthine oxidase with the “Cooperstown cocktail”
DS Streetman, JF Bleakley, JS Kim, AN Nafziger, JS Leeder, A Gaedigk, ...
Clinical Pharmacology & Therapeutics 68 (4), 375-383, 2000
Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N‐acetyltransferase‐2, and xanthine oxidase activities with the …
S Chainuvati, AN Nafziger, JS Leeder, A Gaedigk, GL Kearns, E Sellers, ...
Clinical pharmacology & therapeutics 74 (5), 437-447, 2003
Developmental changes in pharmacokinetics and pharmacodynamics
J van den Anker, MD Reed, K Allegaert, GL Kearns
The Journal of Clinical Pharmacology 58, S10-S25, 2018
Single‐dose pharmacokinetics of ibuprofen and acetaminophen in febrile children
RD Brown, JT Wilson, GL Kearns, VF Eichler, VA Johnson, KM Bertrand
The Journal of Clinical Pharmacology 32 (3), 231-241, 1992
Pharmacokinetics of an elevated dosage of micafungin in premature neonates
PB Smith, TJ Walsh, W Hope, A Arrieta, A Takada, LL Kovanda, ...
The Pediatric infectious disease journal 28 (5), 412, 2009
Ontogeny of Dextromethorphan O‐ and N‐demethylation in the First Year of Life
MJ Blake, A Gaedigk, RE Pearce, LR Bomgaars, ML Christensen, ...
Clinical Pharmacology & Therapeutics 81 (4), 510-516, 2007
Cocaine: clinical pharmacology and toxicology
HC Farrar, GL Kearns
The Journal of pediatrics 115 (5), 665-675, 1989
Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus
B Van Overmeire, D Touw, PJC Schepens, GL Kearns, JN van den Anker
Clinical Pharmacology & Therapeutics 70 (4), 336-343, 2001
The system can't perform the operation now. Try again later.
Articles 1–20